laromustine + cytarabine

Laromustine + cytarabine is a combination of two chemotherapeutic agents used primarily in the treatment of acute myeloid leukemia (AML), particularly in relapsed cases. Laromustine is a sulfonyl hydrazine prodrug that, upon activation, releases the DNA chloroethylating agent 90CE. This agent alkylates the O6 position of guanine in DNA, leading to interstrand cross-links and inhibition of DNA synthesis and repair, resulting in cell death. It also releases methyl isocyanate, which inhibits O6-methylguanine-DNA methyltransferase involved in DNA repair[5][6][8]. Cytarabine is an antimetabolite that interferes with DNA synthesis by inhibiting DNA polymerase during the S-phase of cell division[1][3]. The combination has been studied for its potential to increase complete remission rates compared to high-dose cytarabine alone; however, it was associated with increased toxicity and mortality without improvement in overall survival[4][5].

Other names

cloretazineAra-C